TICKERNERD
Menu
MNKDMNKDHealthcare · Biotechnology

MNKD Stock Forecast: MannKind Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.85
+3.22% on the day

The 8 Wall Street analysts covering MannKind Corp. hold a median 12-month price target of $7.5 — +94.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.2B
Ticker Nerd rank
31 / 100
Median analyst target
$7.50
Analysts covering
8
Total return, dividends reinvested
1W
−6.3%
1M
−0.8%
YTD
−32.1%
1Y
+4.1%
From 52W high
−38.0%
From 52W low
+68.9%
$2.28
$6.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNKD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MannKind Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
85
Volatility
44
Size
44
Accruals
35
Growth
33
Momentum
30
Revisions
27
Issuance
15

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MNKD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNKD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26MNKDHigh $13.00Median $7.50Low $4.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $4.75Median $7.50High $13.00

The green dot is the last close — the median target sits +94.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Aug 2026Wells FargoMaintainsOverweight$14 → $13
30 July 2026Wells FargoMaintainsOverweight$11 → $14
7 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026HC Wainwright & Co.MaintainsBuy$8.00 → $10
7 May 2026MizuhoMaintainsOutperform$8.00 → $7.00
7 May 2026MizuhoMaintainsOutperform—
7 May 2026RBC CapitalMaintainsSector Perform$3.50 → $4.75
7 May 2026RBC CapitalMaintainsSector Perform—
7 May 2026Wells FargoMaintainsOverweight—
7 May 2026Wells FargoMaintainsOverweight$8.00 → $10
28 Apr 2026Wells FargoMaintainsOverweight—
13 Apr 2026MizuhoMaintainsOutperform—
5 Mar 2026WedbushMaintainsOutperform—
27 Feb 2026HC Wainwright & Co.MaintainsBuy—
27 Feb 2026RBC CapitalDowngradeSector Perform—
27 Feb 2026Wells FargoMaintainsOverweight—
25 Feb 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026HC Wainwright& Co.ReiteratesBuy—
26 Jan 2026HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNKD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MNKD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−68.6%
Analysts raising
1
Analysts cutting
0
Fundamentals

MannKind Corp. (MNKD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
193.5×

Cheaper than 4% of US stocks

Price / sales
3.1×

Cheaper than 41% of US stocks

Price / book
−17.7×

Cheaper than 98% of US stocks

EV / EBITDA
55.5×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
42.9%

Higher than 84% of US stocks

Earnings growth (YoY)
42.9%

Higher than 72% of US stocks

Gross margin
73.0%

Higher than 85% of US stocks

Operating margin
−0.8%

Higher than 31% of US stocks

Net margin
−11.1%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−11.5%

Higher than 35% of US stocks

Return on assets
0.8%

Higher than 48% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MNKD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNKDMannKind Corp.$1.2B
31
OMEROmeros Corp.$1.2B
90
EYPTEyePoint, Inc.$1.2B
22
LTGOLatigo Biotherapeutics, Inc.$1.2B
0
REPLReplimune Group, Inc.$1.2B
34
CRVSCorvus Pharmaceuticals, Inc.$1.2B
55
ANROAlto Neuroscience, Inc.$1.2B
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MannKind Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNKD news & analysis

MannKind: New Approvals Majorly Increase MannKind's Prospects

Seeking Alpha · 13 Aug 2026positive

MannKind continues to see modest growth from its three revenue streams, and two new FDA approvals are expected to significantly boost growth in two of its established products. The company's existing liquidity is projected to fund operations and launches for about 2.3 years.

Why it matters — MNKD watchers would care because the two new FDA approvals could materially accelerate growth in established products, reinforcing the company's growth outlook.

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of MannKind Corporation's Q2 2026 earnings call. The transcript covers the company's second-quarter 2026 results and the accompanying management discussion.

Why it matters — The transcript gives MNKD watchers a direct record of management's commentary on the company's latest quarterly performance.

MannKind Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

MannKind reported second-quarter revenue of $109.4 million, up 43% from the prior-year period. Growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.

Why it matters — The quarter shows strong year-over-year revenue growth in MannKind's commercial products and collaboration business despite higher spending on launches and development.

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 6 Aug 2026neutral

Zacks Research reports on MannKind's (MNKD) second-quarter 2026 results, examining how the company's key metrics compare with Wall Street estimates and the year-ago actuals. The piece focuses on contextualising the headline numbers through these comparisons.

Why it matters — MNKD watchers would look to this comparison to gauge how the company's core operating metrics stacked up against analyst expectations and its prior-year performance.

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

MannKind reported a Q2 loss of $0.06 per share, wider than the Zacks Consensus Estimate of a $0.02 loss, compared with break-even earnings per share a year earlier. The company nonetheless beat revenue estimates for the quarter.

Why it matters — MNKD watchers would focus on the per-share loss being larger than analysts expected and worse than the prior-year break-even result, even as revenue came in ahead of estimates.

FAQ

Frequently asked questions about MNKD stock

What is the MNKD stock price forecast for 2026-2027?

The 8 Wall Street analysts covering MannKind Corp. have a median 12-month price target of $7.5, with estimates ranging from $4.75 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNKD stock a buy right now?

Of the 8 analysts covering MannKind Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MannKind Corp. 31 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNKD?

As at 15 Aug 2026, MannKind Corp. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will MNKD stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +94.8% from the last close, and Ticker Nerd's factor model ranks MannKind Corp. 31 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNKD stock forecast for 2030?

No analyst covering MannKind Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNKD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $13 over the next 12 months.

How has MNKD stock performed over the past year?

MannKind Corp. returned +4.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MannKind Corp. do?

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. Its key products include Afrezza, an inhaled insulin for diabetes management; FUROSCIX, a subcutaneous furosemide delivery system for edema associated with chronic heart failure or kidney disease; and Tyvaso DPI, a dry powder inhaler for pulmonary hypertension manufactured in partnership with United Therapeutics.

What is the latest news on MNKD?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "MannKind: New Approvals Majorly Increase MannKind's Prospects". MannKind continues to see modest growth from its three revenue streams, and two new FDA approvals are expected to significantly boost growth in two of its established products. The company's existing liquidity is projected to fund operations and launches for about 2.3 years.

Company

About MannKind Corp.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. Its key products include Afrezza, an inhaled insulin for diabetes management; FUROSCIX, a subcutaneous furosemide delivery system for edema associated with chronic heart failure or kidney disease; and Tyvaso DPI, a dry powder inhaler for pulmonary hypertension manufactured in partnership with United Therapeutics. The company also offers V-Go, an insulin delivery device. MannKind advances a pipeline of dry powder inhalation technologies, such as MNKD-201, a nintedanib formulation for idiopathic pulmonary fibrosis, alongside programs targeting nontuberculous mycobacterial lung disease and other respiratory conditions. Through strategic acquisitions like scPharmaceuticals, MannKind has expanded its cardiometabolic portfolio, emphasizing patient-centric solutions that integrate into daily life. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind Corporation plays a vital role in addressing unmet needs in endocrine and rare pulmonary disorders with its proprietary Technosphere platform.

CEO Dr. Michael E. Castagna Pharm.D. · 591 employees · United States · https://mannkindcorp.com